JP2014513948A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014513948A5 JP2014513948A5 JP2014506508A JP2014506508A JP2014513948A5 JP 2014513948 A5 JP2014513948 A5 JP 2014513948A5 JP 2014506508 A JP2014506508 A JP 2014506508A JP 2014506508 A JP2014506508 A JP 2014506508A JP 2014513948 A5 JP2014513948 A5 JP 2014513948A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- hla
- cells
- chain fusion
- cell according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161477474P | 2011-04-20 | 2011-04-20 | |
| US61/477,474 | 2011-04-20 | ||
| PCT/US2012/034051 WO2012145384A1 (en) | 2011-04-20 | 2012-04-18 | Beta-2 microglobulin-deficient cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018156070A Division JP2018174946A (ja) | 2011-04-20 | 2018-08-23 | β２ミクログロブリン欠損細胞 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014513948A JP2014513948A (ja) | 2014-06-19 |
| JP2014513948A5 true JP2014513948A5 (https=) | 2015-05-28 |
Family
ID=46051930
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014506508A Pending JP2014513948A (ja) | 2011-04-20 | 2012-04-18 | β２ミクログロブリン欠損細胞 |
| JP2018156070A Pending JP2018174946A (ja) | 2011-04-20 | 2018-08-23 | β２ミクログロブリン欠損細胞 |
| JP2020166783A Active JP7260182B2 (ja) | 2011-04-20 | 2020-10-01 | β２ミクログロブリン欠損細胞 |
| JP2023054810A Active JP7586528B2 (ja) | 2011-04-20 | 2023-03-30 | β２ミクログロブリン欠損細胞 |
| JP2024190215A Pending JP2025010296A (ja) | 2011-04-20 | 2024-10-30 | β２ミクログロブリン欠損細胞 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018156070A Pending JP2018174946A (ja) | 2011-04-20 | 2018-08-23 | β２ミクログロブリン欠損細胞 |
| JP2020166783A Active JP7260182B2 (ja) | 2011-04-20 | 2020-10-01 | β２ミクログロブリン欠損細胞 |
| JP2023054810A Active JP7586528B2 (ja) | 2011-04-20 | 2023-03-30 | β２ミクログロブリン欠損細胞 |
| JP2024190215A Pending JP2025010296A (ja) | 2011-04-20 | 2024-10-30 | β２ミクログロブリン欠損細胞 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US20140134195A1 (https=) |
| EP (1) | EP2699593B2 (https=) |
| JP (5) | JP2014513948A (https=) |
| CA (2) | CA3205636A1 (https=) |
| DK (1) | DK2699593T4 (https=) |
| WO (1) | WO2012145384A1 (https=) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3205636A1 (en) | 2011-04-20 | 2012-10-26 | University Of Washington Through Its Center For Commercialization | Beta-2 microglobulin-deficient cells |
| FI2838548T3 (fi) * | 2012-04-17 | 2023-10-02 | Univ Washington Through Its Center For Commercialization | HLA:n luokan II puutteelliset solut, HLA:n luokan II puutteelliset solut, jotka kykenevät ilmentämään HLA:n luokan II proteiineja, ja niiden käytöt |
| CA2896053A1 (en) * | 2012-12-21 | 2014-06-26 | Ocata Therapeutics, Inc. | Methods for production of platelets from pluripotent stem cells and compositions thereof |
| AU2014277092B2 (en) * | 2013-06-03 | 2019-04-04 | Theravectys | Lentiviral vectors containing an MHC class I, MHC class II, or beta-2 microglobulin upstream promoter sequence |
| WO2015121454A1 (en) | 2014-02-14 | 2015-08-20 | Cellectis | Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells |
| JP6681837B2 (ja) | 2014-03-11 | 2020-04-15 | セレクティスＣｅｌｌｅｃｔｉｓ | 同種移植に適合するｔ細胞を作製するための方法 |
| GB201412494D0 (en) * | 2014-07-14 | 2014-08-27 | Ospedale San Raffaele And Fond Telethon | Vector production |
| US20170335331A1 (en) | 2014-10-31 | 2017-11-23 | The Trustees Of The University Of Pennsylvania | Altering Gene Expression in CART Cells and Uses Thereof |
| EP3215623A4 (en) | 2014-11-06 | 2018-09-26 | President and Fellows of Harvard College | Cells lacking b2m surface expression and methods for allogeneic administration of such cells |
| CN116059378A (zh) | 2014-12-10 | 2023-05-05 | 明尼苏达大学董事会 | 用于治疗疾病的遗传修饰的细胞、组织和器官 |
| CN107921148A (zh) | 2015-05-08 | 2018-04-17 | 哈佛学院校长同事会 | 通用供体干细胞和相关方法 |
| JP2019532640A (ja) * | 2016-09-29 | 2019-11-14 | ナントクエスト インコーポレイテッド | 免疫原性が低下したｈｌａクラスｉ欠損ｎｋ−９２細胞 |
| EP3630809A1 (en) * | 2017-05-23 | 2020-04-08 | Bruttel, Valentin | Combinations of mhc class ib molecules and peptides for targeted therapeutic immunomodulation |
| US10391156B2 (en) * | 2017-07-12 | 2019-08-27 | Viacyte, Inc. | University donor cells and related methods |
| JP2020534352A (ja) | 2017-09-07 | 2020-11-26 | キュー バイオファーマ，インコーポレーテッド | コンジュゲーション部位を有するｔ細胞調節多量体ポリペプチド及びその使用方法 |
| KR20200075851A (ko) * | 2017-10-19 | 2020-06-26 | 셀렉티스 | 개선된 면역 세포들 치료를 위한 nk 억제제들의 타겟인 유전자 통합 |
| JP2021507924A (ja) * | 2017-12-22 | 2021-02-25 | ディストリビューテッド バイオ， インコーポレイテッド | 主要組織適合複合体（ｍｈｃ）組成物およびその使用方法 |
| WO2019160077A1 (ja) | 2018-02-16 | 2019-08-22 | 国立大学法人京都大学 | 低抗原性細胞の製造方法 |
| CA3177757A1 (en) * | 2018-02-16 | 2019-08-22 | Kite Pharma, Inc. | Modified pluripotent stem cells and methods of making and use |
| KR102304549B1 (ko) * | 2018-05-30 | 2021-09-27 | 주식회사 강스템바이오텍 | Hla 유전자가 제거된 인간 유도만능줄기세포 유래 중간엽줄기세포 및 그의 제조 방법 |
| US12331318B2 (en) | 2018-07-13 | 2025-06-17 | Lothar Germeroth | Non-immunogenic engineered tissue and methods of producing and using the same |
| JP7669266B2 (ja) | 2018-08-31 | 2025-04-28 | ウィスコンシン アラムニ リサーチ ファンデーション | 動脈内皮細胞を播種した血管移植片の生成 |
| AU2019336221B2 (en) | 2018-09-07 | 2025-05-15 | Wisconsin Alumni Research Foundation | Generation of hematopoietic progenitor cells from human pluripotent stem cells |
| US12378572B2 (en) | 2018-09-07 | 2025-08-05 | Crispr Therapeutics Ag | Universal donor cells |
| WO2020067993A1 (en) * | 2018-09-26 | 2020-04-02 | National University Of Singapore | Engineered human mesenchymal stromal cells with low immunogenicity, methods and kits of generating the same |
| AU2019397033B2 (en) | 2018-12-12 | 2023-06-29 | Kite Pharma, Inc. | Chimeric antigen receptors and CAR-T cells and methods of use |
| CN120174005A (zh) | 2019-02-13 | 2025-06-20 | 比姆医疗股份有限公司 | 具有用于修饰靶标序列中核碱基的腺苷脱氨酶碱基编辑器的经修饰的免疫细胞 |
| KR102691932B1 (ko) | 2019-04-03 | 2024-08-06 | 프리시젼 바이오사이언시스 인코포레이티드 | 마이크로RNA-적응 shRNA(shRNAmiR)를 포함하는 유전자-변형 면역 세포 |
| TW202115245A (zh) | 2019-06-27 | 2021-04-16 | 丹麥商諾佛 儂迪克股份有限公司 | 安全免疫隱形細胞 |
| CA3150235A1 (en) | 2019-09-05 | 2021-03-11 | Alireza Rezania | Universal donor cells |
| PH12022550542A1 (en) | 2019-09-05 | 2023-03-20 | Crispr Therapeutics Ag | Universal donor cells |
| EP4034138A4 (en) | 2019-09-27 | 2024-07-31 | Beam Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIQUID CANCERS |
| KR20220084296A (ko) * | 2019-10-22 | 2022-06-21 | 더 트러스티스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 | 형질전환 돼지, 이의 제조 방법 및 용도, 그리고 인간 면역계 마우스를 제조하는 방법 |
| KR20210090561A (ko) * | 2020-01-10 | 2021-07-20 | 주식회사 엘지화학 | Mhc 및 종양 항원을 동시 발현하는 항원제시세포를 포함하는 조성물 및 이를 이용한 암 치료 |
| CA3175071A1 (en) | 2020-03-11 | 2021-09-16 | Bit Bio Limited | Method of generating hepatic cells |
| US20230348854A1 (en) * | 2020-05-08 | 2023-11-02 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Chimeric antigen receptors (cars) targeting natural killer cells |
| EP4149525A4 (en) * | 2020-05-15 | 2024-08-28 | Rxcell Inc. | HYPOIMMUNOGENIC CELLS AND THEIR USES IN IMMUNE RESPONSES |
| WO2021242935A1 (en) * | 2020-05-26 | 2021-12-02 | Cue Biopharma, Inc. | Antigen presenting polypeptide complexes and methods of use thereof |
| BR112023003036A2 (pt) | 2020-08-19 | 2023-04-25 | Astellas Pharma Inc | Região fc modificada de ocorrência não natural humana de igg especificamente ligando-se a receptor de fc modificado de ocorrência não natural |
| EP4200023A4 (en) * | 2020-08-23 | 2024-10-30 | Applied StemCell, Inc. | Hla-f-modified cells and methods |
| US11459372B2 (en) | 2020-11-30 | 2022-10-04 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| KR20230118887A (ko) | 2020-12-03 | 2023-08-14 | 센츄리 쎄라퓨틱스 인코포레이티드 | 유전자 조작 세포 및 이의 용도 |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| WO2022129472A1 (en) | 2020-12-18 | 2022-06-23 | Novo Nordisk A/S | Safe immuno-stealth cells |
| AR124414A1 (es) | 2020-12-18 | 2023-03-22 | Century Therapeutics Inc | Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable |
| WO2022136215A1 (en) | 2020-12-21 | 2022-06-30 | Novo Nordisk A/S | Safe immuno-stealth cells |
| WO2022144632A1 (en) | 2020-12-30 | 2022-07-07 | Crispr Therapeutics Ag | Compositions and methods for differentiating stem cells into nk cells |
| WO2022144855A1 (en) | 2020-12-31 | 2022-07-07 | Crispr Therapeutics Ag | Universal donor cells |
| TW202246494A (zh) * | 2021-01-26 | 2022-12-01 | 美商艾姆比斯藥品公司 | 基因改造肝細胞群 |
| JPWO2022191216A1 (https=) | 2021-03-09 | 2022-09-15 | ||
| EP4323395A4 (en) * | 2021-04-12 | 2025-04-02 | Memorial Sloan Kettering Cancer Center | MANIPULATED HLA MOLECULES FOR T CELL AND NK CELL ACTIVATION AND EXPANSION |
| CN117242173A (zh) | 2021-05-03 | 2023-12-15 | 安斯泰来再生医药协会 | 产生成熟角膜内皮细胞的方法 |
| WO2022235869A1 (en) | 2021-05-07 | 2022-11-10 | Astellas Institute For Regenerative Medicine | Methods of generating mature hepatocytes |
| EP4359541A4 (en) * | 2021-06-23 | 2025-04-30 | Editas Medicine, Inc. | Engineered cells for therapy |
| WO2023047524A1 (ja) | 2021-09-24 | 2023-03-30 | 公益財団法人京都大学ｉＰＳ細胞研究財団 | 改変ヒト人工多能性幹細胞の製造方法 |
| WO2023069480A1 (en) * | 2021-10-20 | 2023-04-27 | Vascugen, Inc. | Hypoimmune vasculogenic cells |
| CN119072544A (zh) | 2022-04-01 | 2024-12-03 | 株式会社标志融合 | 适合于基因工程、细胞工程和细胞药物的细胞及其制造方法 |
| US20260002124A1 (en) | 2022-07-01 | 2026-01-01 | Novo Nordisk A/S | Enhancing neuronal differentiation of ventral midbrain neural progenitor cells |
| TW202417614A (zh) | 2022-08-23 | 2024-05-01 | 安斯泰來再生醫藥協會 | 用於治療眼部病症的感光救援細胞（prc）組成物及方法 |
| EP4577223A2 (en) * | 2022-08-26 | 2025-07-02 | Beam Therapeutics Inc. | Modified allogeneic cells and methods and compositions for the preparation thereof |
| KR20250090297A (ko) | 2022-10-25 | 2025-06-19 | 다이이찌 산쿄 가부시키가이샤 | 억제형 kir 에 대한 아고니스트를 사용한 면역 거절의 회피 방법 |
| EP4619033A1 (en) * | 2022-11-17 | 2025-09-24 | The Trustees of Indiana University | Novel biomarker and target for treating pulmonary hypertension |
| EP4649150A1 (en) | 2023-01-13 | 2025-11-19 | Laverock Therapeutics Limited | Cell context-specific gene regulation using inhibitory rnas |
| EP4735585A1 (en) | 2023-06-30 | 2026-05-06 | Novo Nordisk A/S | Enhancing neuronal differentiation of neural progenitor cells |
| WO2025070822A1 (ja) * | 2023-09-29 | 2025-04-03 | 味の素株式会社 | Ｈｌａ遺伝子改変細胞 |
| GB202316281D0 (en) * | 2023-10-24 | 2023-12-06 | Replay Holdings Inc | Methods and compositions for modulating immune cell activity in cellular therapy |
| WO2025235955A1 (en) * | 2024-05-10 | 2025-11-13 | Bluerock Therapeutics Lp | Genetically engineered cells for enhanced immune evasion and methods thereof |
| WO2026035951A2 (en) | 2024-08-07 | 2026-02-12 | Legend Biotech Ireland Limited | Cells overexpressing cd43 and methods of use thereof |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5158881A (en) | 1987-11-17 | 1992-10-27 | Brown University Research Foundation | Method and system for encapsulating cells in a tubular extrudate in separate cell compartments |
| US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| US5574205A (en) | 1989-07-25 | 1996-11-12 | Cell Genesys | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| WO1991010470A1 (en) | 1990-01-08 | 1991-07-25 | Brown University Research Foundation | Devices and methods for enhanced delivery of active factors |
| WO1992009688A1 (en) * | 1990-11-21 | 1992-06-11 | Massachusetts Institute Of Technology | MICE HAVING β2 MICROGLOBULIN GENE DISRUPTION |
| WO1993005817A1 (en) | 1991-09-19 | 1993-04-01 | President And Fellows Of Harvard College | Transgenic mhc class i and class ii antigen-deficient mammals |
| CA2110946A1 (en) | 1992-12-09 | 1994-06-10 | Elazar Rabbani | Induction of immunocompatibility by nucleic acid |
| US5837234A (en) | 1995-06-07 | 1998-11-17 | Cytotherapeutics, Inc. | Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane |
| US5869270A (en) | 1996-01-31 | 1999-02-09 | Sunol Molecular Corporation | Single chain MHC complexes and uses thereof |
| WO1998042838A1 (en) | 1997-03-25 | 1998-10-01 | Morphogenesis, Inc. | Universal stem cells |
| US6420518B1 (en) * | 1997-04-04 | 2002-07-16 | Genetech, Inc. | Insulin-like growth factor agonist molecules |
| EP0995798A1 (en) | 1998-10-24 | 2000-04-26 | Novimmune Sa | Transcription factor of MHC class II genes, substances capable of inhibiting this new transcription factor and medical uses of these substances |
| IL151860A0 (en) | 2000-03-27 | 2003-04-10 | Technion Res & Dev Foundation | Single chain class i major histocompatibility complexes, constructs encoding same and methods of generating same |
| DE10132502A1 (de) | 2001-07-05 | 2003-01-23 | Gsf Forschungszentrum Umwelt | Angriff auf Tumorzellen mit fehlender, niedriger oder anormaler MHC-Expression durch kombinieren von nicht MHC-Restringierten T-Zellen/NK-Zellen und MHC-Restringierten Zellen |
| US20040225112A1 (en) | 2003-05-06 | 2004-11-11 | Crew Mark D. | Genes encoding single chain human leukocyte antigen E (HLA-E) proteins to prevent natural killer cell-mediated cytotoxicity |
| FR2856599A1 (fr) | 2003-06-30 | 2004-12-31 | Commissariat Energie Atomique | Utilisation de compositions contenant une forme soluble d'hla-g dans le traitement de pathologies du sang. |
| JP2007508018A (ja) * | 2003-10-08 | 2007-04-05 | べト−ステム インコーポレイテッド | 新規の幹細胞組成物の調製法および使用法、ならびにこの組成物を含有するキット |
| WO2007091078A2 (en) | 2006-02-10 | 2007-08-16 | Axordia Limited | Polypeptide conjugate comprising hla-g and uses thereof, stem cells transfected with hla-g |
| US8105831B2 (en) | 2007-03-09 | 2012-01-31 | University Of Washington | Parvoviral production of HLA homozygous cells |
| US20080299091A1 (en) | 2007-04-06 | 2008-12-04 | International Stem Cell Corporation | Patient-specific stem cell lines derived from human parthenogenetic blastocysts |
| JP5267969B2 (ja) | 2007-12-04 | 2013-08-21 | 学校法人慶應義塾 | 癌ワクチン |
| EP2184297A1 (en) * | 2008-11-07 | 2010-05-12 | Hla-G Technologies | HLA-G polypeptides and pharmaceutical uses thereof |
| AU2011281062B2 (en) | 2010-07-21 | 2015-01-22 | Board Of Regents, The University Of Texas System | Methods and compositions for modification of a HLA locus |
| CA3205636A1 (en) | 2011-04-20 | 2012-10-26 | University Of Washington Through Its Center For Commercialization | Beta-2 microglobulin-deficient cells |
| SG11201500799YA (en) | 2012-07-31 | 2015-03-30 | Basil M Hantash | Hla g-modified cells and methods |
-
2012
- 2012-04-18 CA CA3205636A patent/CA3205636A1/en active Pending
- 2012-04-18 WO PCT/US2012/034051 patent/WO2012145384A1/en not_active Ceased
- 2012-04-18 US US14/111,837 patent/US20140134195A1/en not_active Abandoned
- 2012-04-18 CA CA2833173A patent/CA2833173C/en active Active
- 2012-04-18 DK DK12720040.0T patent/DK2699593T4/da active
- 2012-04-18 JP JP2014506508A patent/JP2014513948A/ja active Pending
- 2012-04-18 EP EP12720040.0A patent/EP2699593B2/en active Active
-
2018
- 2018-08-23 JP JP2018156070A patent/JP2018174946A/ja active Pending
-
2019
- 2019-07-10 US US16/507,589 patent/US11813318B2/en active Active
-
2020
- 2020-10-01 JP JP2020166783A patent/JP7260182B2/ja active Active
-
2023
- 2023-03-30 JP JP2023054810A patent/JP7586528B2/ja active Active
- 2023-10-12 US US18/485,536 patent/US20240207378A1/en active Pending
-
2024
- 2024-10-30 JP JP2024190215A patent/JP2025010296A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014513948A5 (https=) | ||
| JP2018174946A5 (https=) | ||
| Takeuchi et al. | CD4 CTL, a cytotoxic subset of CD4+ T cells, their differentiation and function | |
| JP2022162047A5 (https=) | ||
| Raicevic et al. | Influence of inflammation on the immunological profile of adult-derived human liver mesenchymal stromal cells and stellate cells | |
| Della Chiesa et al. | Human NK cells and herpesviruses: mechanisms of recognition, response and adaptation | |
| Correia et al. | IL-15 induces CD8+ T cells to acquire functional NK receptors capable of modulating cytotoxicity and cytokine secretion | |
| Rölle et al. | CD2–CD58 interactions are pivotal for the activation and function of adaptive natural killer cells in human cytomegalovirus infection | |
| Zhang et al. | Cardiac repair with a novel population of mesenchymal stem cells resident in the human heart | |
| Liu et al. | Low immunogenicity of neural progenitor cells differentiated from induced pluripotent stem cells derived from less immunogenic somatic cells | |
| EP4609876A3 (en) | Anti-human papillomavirus 16 e7 t cell receptors | |
| Körner et al. | Increased frequency and function of KIR2DL1–3+ NK cells in primary HIV‐1 infection are determined by HLA‐C group haplotypes | |
| IL273267B2 (en) | Carriers of DNA that do not undergo integration for genetic modification of cells | |
| EP4623996A3 (en) | COMPOSITIONS AND METHODS FOR IDENTIFYING TUMOR-SPECIFIC NEOANTIGENS | |
| JP2014513983A5 (https=) | ||
| Wang et al. | How important is differentiation in the therapeutic effect of mesenchymal stromal cells in liver disease? | |
| Stockinger et al. | CD4 T-cell memory | |
| US20170267972A1 (en) | Production method for pluripotent stem cells having antigen-specific t cell receptor gene | |
| JP2019508044A5 (https=) | ||
| RU2020117772A (ru) | Векторы | |
| Daniel et al. | CD4+ CD25+ Foxp3+ IFNγ+ CD178+ human induced Treg (iTreg) contribute to suppression of alloresponses by apoptosis of responder cells | |
| Jung et al. | KIR3DS1 directs NK cell–mediated protection against human adenovirus infections | |
| JP2014508527A5 (https=) | ||
| Dörrie et al. | Human adenovirus-specific γ/δ and CD8+ T cells generated by T-cell receptor transfection to treat adenovirus infection after allogeneic stem cell transplantation | |
| TR201905447T4 (tr) | Yeni mhc bağımsız tümörle ilişkili antijenler. |